Literature DB >> 22828140

Improvements in quality of life after surgery for benign hepatic tumors: Results from a dual center analysis.

Peter J Kneuertz1, J Wallis Marsh, Mechteld C de Jong, Keaton Covert, Omar Hyder, Kenzo Hirose, Richard D Schulick, Michael A Choti, David A Geller, Timothy M Pawlik.   

Abstract

BACKGROUND: Outcomes after operative management of benign hepatic lesions are ill-defined. We sought to define patient-reported quality of life (QOL) postoperatively for benign hepatic tumors.
METHODS: Patients who underwent surgery for benign liver lesions (n = 255) were invited to complete a QOL survey designed using validated assessment tools. Clinicopathologic data were collected from 2 participating hepatobiliary centers and correlated with QOL data.
RESULTS: The response rate was 70.2%. Most patients had a benign cystic (41.9%) or solid (47.5%) tumor; 19 (10.6%) patients had an indeterminate lesion. The lesion was most often solitary (71.5%) and median size was 7.5 cm. Most benign lesions were either a simple cyst (35.8%), hemangioma (19.6%), focal nodular dysplasia (19.6%), or hepatic adenoma (16.9%). Presenting symptoms included abdominal pain (70.9%), nausea/vomiting (5.0%), and early satiety (5.0%). Surgery involved less than hemihepatectomy (68.2%); a laparoscopic approach was utilized in 40.8% of patients. Perioperative morbidity was 16%. Postoperatively, the proportion of patients who reported moderate-to-extreme pain decreased from 46.9% to 15.6% and 6.8% at 6 months and 1-year, respectively (P < .001). Patient self-reported mean pain scores also decreased over time (preoperative, 1.65 vs 6 months, 0.63 vs 1 year, 0.28; P < .001). Patients with "moderate-to-extreme" pain preoperatively were more likely to report an improvement in pain scores (odds ratio, 1.96; 95% confidence interval, 1.05-3.66; P = .03). Many patients reported overall improvement in general health (40.5%) and physical health (39.3%; P < .001).
CONCLUSION: Surgery for benign liver lesions is associated with high patient satisfaction and improved QOL. Patients with significant preoperative symptoms derive the most benefit from surgery.
Copyright © 2012 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22828140     DOI: 10.1016/j.surg.2012.05.004

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  10 in total

1.  Evaluation of Selective Arterial Embolization Effect by Chitosan Micro-Hydrogels in Hindlimb Sarcoma Rodent Models Using Various Imaging Modalities.

Authors:  Tai Kyoung Lee; JeongIl Kwon; Kyung Sook Na; Hwan-Seok Jeong; Hyosook Hwang; Phil-Sun Oh; Dong Hyun Kim; Kyu Yun Jang; Seok Tae Lim; Myung-Hee Sohn; Hwan-Jeong Jeong
Journal:  Nucl Med Mol Imaging       Date:  2015-01-28

Review 2.  Benign solid tumors of the liver: management in the modern era.

Authors:  Georgios Antonios Margonis; Aslam Ejaz; Gaya Spolverato; Neda Rastegar; Robert Anders; Ihab R Kamel; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2015-01-06       Impact factor: 3.452

3.  A Cross-Sectional Evaluation of Quality of Life Among Patients with Hepatic Adenomas.

Authors:  Emily A Armstrong; Aslam Ejaz; Angela Sarna; Lanla Conteh; Allan Tsung; Timothy M Pawlik; Jordan M Cloyd
Journal:  J Gastrointest Surg       Date:  2020-12       Impact factor: 3.452

4.  Long-term outcomes of resection in patients with symptomatic benign liver tumours.

Authors:  Belle V van Rosmalen; Matthanja Bieze; Marc G H Besselink; Pieter Tanis; Joanne Verheij; Saffire S K S Phoa; Olivier Busch; Thomas M van Gulik
Journal:  HPB (Oxford)       Date:  2016-08-21       Impact factor: 3.647

5.  Transarterial embolization with bleomycin for symptomatic hepatic focal nodular hyperplasia.

Authors:  Guodong Zhang; Maoqiang Wang; Feng Duan; Kai Yuan; Kai Li; Jieyu Yan; Zhongfei Chang
Journal:  Diagn Interv Radiol       Date:  2017 Jan-Feb       Impact factor: 2.630

6.  National trends in the use of surgery for benign hepatic tumors in the United States.

Authors:  Yuhree Kim; Neda Amini; Jin He; Georgios A Margonis; Matthew Weiss; Christopher L Wolfgang; Martin Makary; Kenzo Hirose; Gaya Spolverato; Timothy M Pawlik
Journal:  Surgery       Date:  2015-03-11       Impact factor: 3.982

7.  A risk model to predict 90-day mortality among patients undergoing hepatic resection.

Authors:  Omar Hyder; Carlo Pulitano; Amin Firoozmand; Rebecca Dodson; Christopher L Wolfgang; Michael A Choti; Luca Aldrighetti; Timothy M Pawlik
Journal:  J Am Coll Surg       Date:  2013-03-09       Impact factor: 6.113

8.  Surgical management of hepatic hemangiomas: a multi-institutional experience.

Authors:  John T Miura; Albert Amini; Ryan Schmocker; Shawnn Nichols; Daniel Sukato; Emily R Winslow; Gaya Spolverato; Aslam Ejaz; Malcolm H Squires; David A Kooby; Shishir K Maithel; Aijun Li; Meng-Chao Wu; Juan M Sarmiento; Mark Bloomston; Kathleen K Christians; Fabian M Johnston; Susan Tsai; Kiran K Turaga; Allan Tsung; Timothy M Pawlik; T Clark Gamblin
Journal:  HPB (Oxford)       Date:  2014-06-19       Impact factor: 3.647

9.  2012 Liver resections in the 21st century: we are far from zero mortality.

Authors:  Safi Dokmak; Fadhel Samir Ftériche; René Borscheid; François Cauchy; Olivier Farges; Jacques Belghiti
Journal:  HPB (Oxford)       Date:  2013-03-06       Impact factor: 3.647

10.  The value of liver resection for focal nodular hyperplasia: resection yes or no?

Authors:  Hans Michael Hau; Georgi Atanasov; Hans-Michael Tautenhahn; Rudolf Ascherl; Georg Wiltberger; Markus Bo Schoenberg; Mehmet Haluk Morgül; Dirk Uhlmann; Michael Moche; Jochen Fuchs; Moritz Schmelzle; Michael Bartels
Journal:  Eur J Med Res       Date:  2015-10-22       Impact factor: 2.175

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.